ADI-270
- Generic Name
- ADI-270
A Phase 1/2 Trial of ADI-270 in CcRCC
Phase 1
Recruiting
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Adicet Therapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT06480565
- Locations
- 🇺🇸
Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath